11 Countries' Medical Staff Visit Celltrion Healthcare... IBD Homecoming Day Held

Sharing Key Data on Remsima SC and Uplima

Celltrion Healthcare announced on the 16th that it will hold the 'Global IBD Homecoming Day 2023' for five days from the 14th to the 18th, targeting key medical professionals from around the world.

On the 14th, medical staff attending the 'Global IBD Homecoming Day 2023' event visited the Celltrion Global Biotechnology Research Center to receive an overview of the company's overall business.
[Photo by Celltrion Healthcare]

This Homecoming Day was prepared to promote the competitiveness of Celltrion Group's Inflammatory Bowel Disease (IBD) treatments. Celltrion Healthcare hosts homecoming events inviting key stakeholders from Europe, the Americas, Asia, and other regions to Korea, sharing not only product promotion but also the latest domestic and international medical trends and prescription cases. Approximately 40 core medical professionals in the IBD field from 11 countries, including Canada, Australia, and the Czech Republic, attended this event.

On the first day of the event, Celltrion Healthcare introduced the unique features and real-world data of its products, including 'Remsima SC' (U.S. product name: Gyompentra), recently approved as a new drug in the United States, and 'Yuflyma' (generic name: adalimumab), during the marketing session.

According to Celltrion Healthcare, attendees showed high engagement during the subsequent medical session, discussing efficacy and safety data related to dose escalation and monotherapy of Remsima SC confirmed through post-analysis of global Phase 3 clinical trials. Additionally, the company provided explanations on drug development status and production processes through tours of Celltrion's second plant and the Global Biotechnology Research Center.

On the second day, the 15th, meetings were held with domestic medical staff at the Department of Gastroenterology, Asan Medical Center in Seoul. Speakers and attendees exchanged opinions on IBD-related treatment trends and patient cases experienced in actual medical practice. From the 16th, they participated in the 7th International Digestive Disease Week Korea (KDDW 2023) held at the Grand Walkerhill Seoul.

A representative from Celltrion Healthcare stated, "In this homecoming event, in-depth discussions on research data of key products such as Remsima SC and Yuflyma attracted great interest from attendees. Moving forward, we will strengthen marketing activities targeting not only medical professionals but also patient associations and medical societies to promote the excellence of Celltrion Group's biopharmaceuticals globally and solidify our position in the IBD market."

This content was produced with the assistance of AI translation services.